Boston, June 13, 2024 (GLOBE NEWSWIRE) -- Amwell® (NYSE: AMWL), a leader in digital care, today announced that co-founder and visionary healthcare technology leader Roy Schoenberg, M.D., M.P.H., is transitioning from his role as president and co-CEO to become Executive Vice Chairman of Amwell’s Board of Directors. Ido Schoenberg, M.D., will assume the role of sole Chief Executive Officer of Amwell.
Since co-founding Amwell in 2006, Roy Schoenberg has been a driving force behind the nation’s embrace of digital healthcare. His vision of democratizing the availability and distribution of healthcare, using modern technology, laid the foundation for how patients and clinicians experience digital care. His relentless pursuit to advance our view of the possible helped the industry welcome new efficiencies, embrace care automation, healthcare AI and related technologies, and further elevate how and where patients can be cared for. When the COVID-19 pandemic disrupted in-person care, he worked tirelessly with payers, providers and regulators to ensure the industry could keep its obligation to its patients, using technology. While doing so, Roy Schoenberg helped grow the Amwell platform to reach over 100,000 active clinicians and many millions of patients annually across the globe. As the world recovered from the pandemic, he began to architect a next-generation platform – the Amwell Converge™ platform – to support a fast-evolving world of expectations where care is rendered as a balance of in-person and digital experiences. Bringing healthcare to patients has been Roy Schoenberg’s mission and continues to be Amwell’s.
“The time is now to take the next step in our mission. Our unique opportunity to realize the immense value in new Amwell technology – while achieving critical operational and clinical goals – is both timely and exciting. I am confident in our talented leadership team and will continue to support them in our journey to digitally reimagine healthcare,” said Roy Schoenberg, newly appointed Amwell Executive Vice Chairman.
“This transition represents a natural evolution for our company as we shift from a period of intense R&D investment to an operational focus aimed at achieving greater efficiencies, optimizing cash flow and delivering profitable growth while maintaining our dedication to enabling our clients’ aspirations,” said Ido Schoenberg. “Roy’s vision, leadership and unwavering dedication has resulted in the creation of a powerful, innovative enterprise technology that has helped establish Amwell as a global provider of world-class software that enables hybrid care delivery.”
Last Trade: | US$7.87 |
Daily Change: | 0.03 0.38 |
Daily Volume: | 77,920 |
Market Cap: | US$107.580M |
December 18, 2024 October 30, 2024 October 08, 2024 July 31, 2024 |
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MOREChimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB